内科学
医学
逻辑回归
接收机工作特性
甲状腺癌
尤登J统计
肿瘤科
甲状腺癌
疾病
病态的
癌症
甲状腺
作者
Louise Schubert,A. M. Mbekwe-Yepnang,Johanna Wassermann,Y. Braik-Djellas,Loïc Jaffrelot,Filippo Eros Pani,Gabrielle Deniziaut,Charlotte Lussey‐Lepoutre,Nathalie Chéreau,Laurence Leenhardt,Marie‐Odile Bernier,C Buffet
标识
DOI:10.1007/s40618-024-02352-z
摘要
Abstract Purpose Risk factors for developing radioiodine refractory thyroid cancer (RAIR-TC) have rarely been analyzed. The purpose of the present study was to find clinical and pathological features associated with the occurrence of RAIR-disease in differentiated thyroid cancers (DTC) and to establish an effective predictive risk score. Methods All cases of RAIR-DTC treated in our center from 1990 to 2020 were retrospectively reviewed. Each case was matched randomly with at least four RAI-avid DTC control patients based on histological and clinical criteria. Conditional logistic regression was used to examine the association between RAIR-disease and variables with univariate and multivariate analyses. A risk score was then developed from the multivariate conditional logistic regression model to predict the risk of refractory disease occurrence. The optimal cut-off value for predicting the occurrence of RAIR-TC was assessed by receiver operating characteristic (ROC) curves and Youden’s statistic. Results We analyzed 159 RAIR-TC cases for a total of 759 controls and found 7 independent risk factors for predicting RAIR-TC occurrence: age at diagnosis ≥ 55, vascular invasion, synchronous cervical, pulmonary and bone metastases at initial work-up, cervical and pulmonary recurrence during follow-up. The predictive score of RAIR-disease showed a high discrimination power with a cut-off value of 8.9 out of 10 providing 86% sensitivity and 92% specificity with an area under the curve (AUC) of 0.95. Conclusion Predicting the occurrence of RAIR-disease in DTC patients may allow clinicians to focus on systemic redifferentiating strategies and/or local treatments for metastatic lesions rather than pursuing with ineffective RAI-therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI